Evolus' (EOLS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS - Free Report) in a report published on Thursday,Benzinga reports. The firm currently has a $27.00 price target on the stock.

Several other equities research analysts also recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Barclays upped their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, September 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Stock Performance

EOLS traded down $2.41 during midday trading on Thursday, reaching $14.40. The company had a trading volume of 1,446,540 shares, compared to its average volume of 582,567. The business has a 50-day moving average price of $16.29 and a two-hundred day moving average price of $13.83. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. Evolus has a 12-month low of $7.74 and a 12-month high of $17.82. The stock has a market cap of $908.50 million, a PE ratio of -16.78 and a beta of 1.31.

Evolus (NASDAQ:EOLS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The business had revenue of $61.09 million during the quarter, compared to analysts' expectations of $62.81 million. On average, sell-side analysts expect that Evolus will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EOLS. Oppenheimer & Co. Inc. bought a new position in Evolus in the third quarter worth $212,000. GSA Capital Partners LLP increased its stake in shares of Evolus by 335.3% in the 3rd quarter. GSA Capital Partners LLP now owns 120,964 shares of the company's stock worth $1,960,000 after acquiring an additional 93,176 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in Evolus by 6.3% during the third quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company's stock worth $14,659,000 after acquiring an additional 53,605 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company's stock worth $197,000 after purchasing an additional 4,780 shares during the period. Finally, Semanteon Capital Management LP bought a new stake in shares of Evolus in the 3rd quarter worth approximately $912,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.